<DOC>
	<DOCNO>NCT00375752</DOCNO>
	<brief_summary>This study evaluate safety/efficacy zoledronic acid give intravenous infusion every 4 week addition letrozole endocrine therapy postmenopausal patient hormone responsive breast cancer</brief_summary>
	<brief_title>Efficacy Safety Letrozole vs. Letrozole Plus Zoledronic Acid Endocrine Therapy Before Surgery Postmenopausal Patients With Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criterion : Postmenopausal woman primary invasive breast cancer , histologically confirm core needle biopsy , whose tumor estrogen ( ER ) / progesterone ( PgR ) positive Clinical Stage T1c ( Size ≥ 1.5 cm ) , T2 , T3 , T4a , b , c , N0 N1 , M0 ( TNM Classification ) . According modified RECIST criterion , tumor size ≥ 1.5 cm consider measurable mammography determine target lesion ) . Tumor measurable mammography , sonography clinical examination . Adequate bone marrow , renal hepatic function Good health status ( ECOG Performance status 0 , 1 2 ) Exclusion criterion : Prior treatment letrozole bisphosphonates . Prior concomitant antibreastcancer treatment chemotherapy , immunotherapy / biological response modifier ( BRM 's ) , endocrine therapy letrozole ( include steroid ) , radiotherapy . Patients receive hormone replacement therapy ( HRT ) NOT exclude , provide HRT discontinue least 2 week prior entry study . Patients unstable angina , uncontrolled cardiac disease ( e.g . Class III IV New York Heart Association 's Functional Classification , see Appendix 9 ) uncontrolled endocrine disorder . Evidence inflammatory breast cancer distant metastasis . Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery ( e.g . extraction , implant ) . History diseases influence bone metabolism , Paget 's disease , Osteogenesis Imperfecta , primary secondary hyperthyroidism within 12 month prior study entry Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Anti tumor potential</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Zoledronic acid</keyword>
	<keyword>Neoadjuvant treatment</keyword>
	<keyword>Hormone responsive breast cancer</keyword>
</DOC>